BE1002406A5 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques. Download PDF

Info

Publication number
BE1002406A5
BE1002406A5 BE8900997A BE8900997A BE1002406A5 BE 1002406 A5 BE1002406 A5 BE 1002406A5 BE 8900997 A BE8900997 A BE 8900997A BE 8900997 A BE8900997 A BE 8900997A BE 1002406 A5 BE1002406 A5 BE 1002406A5
Authority
BE
Belgium
Prior art keywords
weight
carbonate
acceptable salt
physiologically acceptable
pharmaceutical compositions
Prior art date
Application number
BE8900997A
Other languages
English (en)
Inventor
Christopher William Quirk
David Arthur Jackson
James Murray Cameron
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888822071A external-priority patent/GB8822071D0/en
Priority claimed from GB898905995A external-priority patent/GB8905995D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1002406A5 publication Critical patent/BE1002406A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique utilisable en médecine humaine ou vétérinaire. Ella a pour objet une composition qui comprend de la ranitidine ou un sel physiologiquement acceptable de ce composé, de l'acide alginique ou un sel physiologiquement acceptable de cet acide et un carbonate ou bi-carbonate. L'invention comprend de préférence de 1,25 à 10% en poids de chlorhydrate de ranitidin, et 5 à 35 % en poids d'acide alginique et de 2 à 15 % en poids de bicarbonate de sodium et est de préférence sous la forme d'une capsule ou d'un comprimé. Les compositions sont utilisables pour le traitement de troubles gastro-intestinaux et en particulier de l'oesophagite à reflux.
BE8900997A 1988-09-20 1989-09-19 Compositions pharmaceutiques. BE1002406A5 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888822071A GB8822071D0 (en) 1988-09-20 1988-09-20 Medicaments
GB898905995A GB8905995D0 (en) 1989-03-15 1989-03-15 Medicaments

Publications (1)

Publication Number Publication Date
BE1002406A5 true BE1002406A5 (fr) 1991-01-29

Family

ID=26294415

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900997A BE1002406A5 (fr) 1988-09-20 1989-09-19 Compositions pharmaceutiques.

Country Status (13)

Country Link
US (1) US5456918A (fr)
JP (1) JPH0482832A (fr)
AU (1) AU627775B2 (fr)
BE (1) BE1002406A5 (fr)
CA (1) CA1327748C (fr)
CH (1) CH679373A5 (fr)
DE (1) DE3931215C2 (fr)
FR (1) FR2636532B1 (fr)
GB (1) GB2222772B (fr)
IE (1) IE60726B1 (fr)
IT (1) IT1232677B (fr)
NL (1) NL8902338A (fr)
NZ (1) NZ230701A (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
EP0484106A1 (fr) * 1990-11-01 1992-05-06 Merck & Co. Inc. Compositions à libération contrôlée
FR2669822B1 (fr) * 1990-12-03 1993-11-19 Fabre Medicament Pierre Composition pharmaceutique a base d'acide alginique se presentant sous forme d'une mousse.
FR2674437B1 (fr) * 1991-03-29 1993-07-09 Pf Medicament Composition pharmaceutique, utile notamment dans le traitement d'affections gastro-óoesophagiennes.
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
WO1995001795A1 (fr) * 1993-07-06 1995-01-19 Merck & Co., Inc. Combinaison antiacide-alginate-antagoniste h¿2?
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
FI103442B (fi) * 1993-09-24 1999-06-30 Nokia Telecommunications Oy Digitaalinen radiolinkkijärjestelmä ja radiolinkkilaite
ZA947553B (en) * 1993-09-30 1995-05-26 Glaxo Inc Ranitidine and calcium carbonate pharmaceutical combination product
ES2089949B1 (es) * 1993-10-28 1997-08-01 Robert S A Lab Nueva asociacion medicamentosa de hidroxi-bis-(18-beta-glicirretato) de aluminio y ranitidina.
CA2175225C (fr) * 1993-10-29 2004-09-21 Keith Graeme Hutchison Substance a pouvoir moussant garnissant une gelule de gelatine
WO1995011668A1 (fr) * 1993-10-29 1995-05-04 Reckitt & Colman Products Limited Substance a pouvoir moussant garnissant une gelule de gelatine
US5888540A (en) * 1993-10-29 1999-03-30 Sugden; Keith Pharmaceutical products
GB9322314D0 (en) * 1993-10-29 1993-12-15 Scherer Ltd R P Foam generating capsules
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
GB9504599D0 (en) * 1995-03-03 1995-04-26 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
WO1996039126A2 (fr) * 1995-06-06 1996-12-12 Warner-Lambert Company Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
RU2131264C1 (ru) * 1996-06-04 1999-06-10 Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко Противоязвенное средство в виде таблеток и способ его получения
JP2001509791A (ja) * 1996-11-27 2001-07-24 ザ、プロクター、エンド、ギャンブル、カンパニー 胃腸障害の治療用組成物及び方法
GB9715423D0 (en) * 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
HUP9701293A3 (en) * 1997-07-25 1999-08-30 Chinoin Gyogyszer Es Vegyeszet New salts without unsavoury taste and pharmaceutical compositions containing them
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6187334B1 (en) * 1998-09-09 2001-02-13 Kewpie Kabushiki Kaisha Foods for preventing vomiting
GB0005743D0 (en) * 2000-03-10 2000-05-03 Reckitt & Colmann Prod Ltd Pharmaceutical compositions including alginates
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
WO2005018613A1 (fr) * 2003-08-26 2005-03-03 Mandapro Ag Comprimes pour l'administration par voie orale de principes actifs pharmaceutiques
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
DE102006037298A1 (de) 2006-08-08 2008-02-14 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung, insbesondere Antazidum
WO2008106646A2 (fr) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Procédés et formulations pour une thérapie génique topique
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
JP6270637B2 (ja) * 2014-06-06 2018-01-31 ライオン株式会社 錠剤及びその製造方法
CN115518049B (zh) * 2022-11-03 2023-02-17 则正(济南)生物科技有限公司 一种盐酸雷尼替丁胶囊及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000825A1 (fr) * 1986-08-01 1988-02-11 Smith Kline & French Laboratories Limited Compositions pharmacutiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390683A (en) * 1972-12-18 1975-04-16 Biorex Laboratories Ltd Pharmaceutical composition
SE7504049L (sv) * 1975-04-09 1976-10-10 Haessle Ab Colonpreparation
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
GB1524740A (en) * 1976-11-09 1978-09-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions for use in the suppression of gastric reflux
US4316888A (en) * 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
DE3152319C2 (de) * 1980-09-03 1986-05-07 Kyosei Pharmaceutical Co., Ltd., Hokkaido Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
CA1208558A (fr) * 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
US4869902A (en) * 1984-04-19 1989-09-26 Rorer Pharmaceutical Corporation Antacid composition
US4636498A (en) * 1984-10-11 1987-01-13 Pfizer Inc. Formulation of antiinflammatory drugs
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
US4814341A (en) * 1986-08-26 1989-03-21 Reiter Lawrence A 2-guanidino-4-(2-furyl) thiazoles as antiulcer agents
KR960011236B1 (ko) * 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
HU201683B (en) * 1987-08-04 1990-12-28 Biogal Gyogyszergyar Process for producing pharmaceutical compositions for promoting healing of wounds
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000825A1 (fr) * 1986-08-01 1988-02-11 Smith Kline & French Laboratories Limited Compositions pharmacutiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 73, 1982, résumé no. 85480, Biological Abstracts, Inc., Philadelphia, PA, US; I.C.E. WESDORP et al.: "Effect of long-term treatment with cimetidine and anti acids in barretts esophagus", & GUT(ENGLAND) 1981 (RECD. 1982), 22(9), 724-727 *
BR. J. CLIN. PRACT., vol. 43, no. 3, mars 1989, Hove, GB; M. CHANDRA et al.: "Comparative study of alginate and non-alginate antacids concurrently administered with H2 antagonists in cases of duodenal ulcer" *
DICTIONNAIRE VIDAL, 1985, OVP, Paris, FR; "GAVISCON - granulés et comprimés", page 611 *

Also Published As

Publication number Publication date
CA1327748C (fr) 1994-03-15
AU627775B2 (en) 1992-09-03
IE892998L (en) 1990-03-20
NZ230701A (en) 1992-01-29
US5456918A (en) 1995-10-10
GB2222772A (en) 1990-03-21
DE3931215A1 (de) 1990-03-22
IT1232677B (it) 1992-03-03
NL8902338A (nl) 1990-04-17
JPH0482832A (ja) 1992-03-16
IT8948382A0 (it) 1989-10-19
GB2222772B (en) 1992-05-13
FR2636532B1 (fr) 1993-11-19
GB8921188D0 (en) 1989-11-08
DE3931215C2 (de) 1998-07-16
IE60726B1 (en) 1994-08-10
AU4148989A (en) 1990-03-29
FR2636532A1 (fr) 1990-03-23
CH679373A5 (fr) 1992-02-14

Similar Documents

Publication Publication Date Title
BE1002406A5 (fr) Compositions pharmaceutiques.
TW589174B (en) Agent for treating high-risk impaired glucose tolerance
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
ATE69378T1 (de) Pharmazeutische zusammensetzungen.
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
BE1002249A4 (fr) Compositions pharmaceutiques.
BE899635A (fr) Compositions pharmaceutiques.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
TNSN96107A1 (fr) Benzylaminopiperidines substitues et compositions pharmaceutiques les contenant
FR2417982A1 (fr) Produit pharmaceutique solide contenant un sel de bismuth, administrable par voie orale, presentant un taux d'activite accru et un taux de solubilite constant et predetermine
BE901073A (fr) Composition antidiuretique a usage oral.
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
HUT53284A (en) System ensuring controlled release of active ingredient and process for the production thereof
ES2245372T3 (es) Tratamiento de trastornos inflamatorios.
JP3982889B2 (ja) イブプロフェン含有医薬製剤
US6420388B1 (en) Osanetant in the treatment of depression and depressive disorders
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
CA2368352A1 (fr) Procede de traitement de la neuro degenerescence
MA27157A1 (fr) Methode de traitement d'affections osseuses.
BE1002256A3 (fr) Medicaments.
EP0178299A1 (fr) Forme de dosage orale a liberation entretenue pour naproxyn
JPH03193730A (ja) 治療剤
DE3518559A1 (de) Neue verwendung von dihydroergotamin

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: *GLAXO GROUP LTD

Effective date: 20020930